Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats

Neuroscience

Volumn 131, Issue 3, 2005, Pages 705-715

  Butler, M ^a   Hayes, C S ^b   Chappell, A ^a   Murray, S F ^a   Yaksh, T L ^b   Hua, X Y ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b University of California   (United States)

Author keywords

Antisense; Distribution; Immunocytochemistry; Intrathecal; Metabolism; Oligonucleotides

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 11300; ISIS 13920; ISIS 22703; MESSENGER RNA; PROTEIN KINASE C ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CELL TYPE; CEREBROSPINAL FLUID; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG METABOLISM; DRUG TARGETING; DRUG UPTAKE; GEL ELECTROPHORESIS; GENE TARGETING; GLIA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INJECTION; INTRACELLULAR SPACE; LUMBAR SPINAL CORD; MALE; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; SPINAL CORD; SPINAL GANGLION;

EID: 13844311614     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2004.11.038     Document Type: Article

References (49)

1. S. Agrawal, J. Temsamani, W. Galbraith, J. Tang Pharmacokinetics of antisense oligonucleotides Clin Pharmacokinet 28 1995 7 16
2. S. Agrawal, J. Temsamani, J.Y. Tang Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice Proc Natl Acad Sci USA 88 1991 7595 7599
3. B.F. Baker, S.S. Lot, T.P. Condon, S. Cheng-Flournoy, E.A. Lesnik, H.M. Sasmor, C.F. Bennett 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells J Biol Chem 272 1997 11994 12000
4. J. Barclay, S. Patel, G. Dorn, G. Wotherspoon, S. Moffatt, L. Eunson, S. Abdel'al, F. Natt, J. Hall, J. Winter, S. Bevan, W. Wishart, A. Fox, P. Ganju Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain J Neurosci 22 2002 8139 8147
5. C. Beltinger, H.U. Saragovi, R.M. Smith, L. LeSauteur, N. Shah, L. DeDionisio, L. Christensen, A. Raible, L. Jarett, A.M. Gerwitz Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides J Clin Invest 95 1995 1814 1823
6. L. Benimetskaya, J.L. Tonkinson, M. Koziolkiewicz, B. Karwowski, P. Guga, R. Zeltser, W. Stec, C.A. Stein Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent Nucleic Acids Res 23 1995 4239 4245
7. C.F. Bennett, N. Dean, D.J. Ecker, B.P. Monia Pharmacology of antisense therapeutic agents cancer and inflammation S. Agrawal Methods in molecular medicine antisense therapeutics 1996 Humana Press Inc Totowa, NJ 13 46
8. M. Butler, K. Stecker, C.F. Bennett Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues Lab Invest 77 1997 379 388
9. P.D. Cook Antisense medicinal chemistry S.T. Crooke Antisense research and application Vol. 131 1998 Springer-Verlag Berlin 51 101
10. P.A. Cossum, H. Sasmor, D. Dellinger, L. Truong, L. Cummins, S.R. Owens, P.M. Markham, J.P. Shea, S.T. Crooke Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats J Pharmacol Exp Ther 267 1993 1181 1190
11. S.T. Crooke Molecular mechanisms of action of antisense drugs Biochim Biophys Acta 1489 1999 31 43
12. P. Estibeiro, J. Godfray Antisense as a neuroscience tool and therapeutic agent Trends Neurosci 24 2001 S56 S62
13. S.M. Freier, K.H. Altmann The ups and downs of nucleic acid duplex stability structure-stability studies on chemically-modified DNA:RNA duplexes Nucleic Acids Res 25 1997 4429 4443
14. M.E. Fundytus, K. Yashpal, J.G. Chabot, M.G. Osborne, C.D. Lefebvre, A. Dray, J.L. Henry, T.J. Coderre Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats Br J Pharmacol 132 2001 354 367
15. R.S. Geary, R.Z. Yu, T. Watanabe, S.P. Henry, G.E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, A.A. Levin Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide comparison across species Drug Metab Dispos 31 2003 1419 1428
16. F. Gillardon, H. Beck, E. Uhlmann, T. Herdegen, J. Sandkuhler, A. Peyman, M. Zimmermann Inhibition of c-Fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion Eur J Neurosci 6 1994 880 884
17. J.M. Glover, J.M. Leeds, T.G. Mant, D. Amin, D.L. Kisner, J.E. Zuckerman, R.S. Geary, A.A. Levin, W.R. Shanahan Jr Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) J Pharmacol Exp Ther 282 1997 1173 1180
18. M.J. Graham, S.T. Crooke, D.K. Monteith, S.R. Cooper, K.M. Lemonidis, K.K. Stecker, M.J. Martin, R.M. Crooke In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration J Pharmacol Exp Ther 286 1998 447 458
19. S.P. Henry, K. Stecker, D. Brooks, D. Monteith, B. Conklin, C.F. Bennett Chemically modified oligonucleotides exhibit decreased immune stimulation in mice J Pharmacol Exp Ther 292 2000 468 479
20. P. Honore, K. Kage, J. Mikusa, A.T. Watt, J.F. Johnston, J.R. Wyatt, C.R. Faltynek, M.F. Jarvis, K. Lynch Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats Pain 99 2002 11 19
21. X.Y. Hua, P. Chen, E. Polgar, I. Nagy, M. Marsala, E. Phillips, L. Wollaston, L. Urban, T.L. Yaksh, M. Webb Spinal neurokinin NK1 receptor down-regulation and antinociception effects of spinal NK1 receptor antisense oligonucleotides and NK1 receptor occupancy J Neurochem 70 1998 688 698
22. X.Y. Hua, A. Moore, S. Malkmus, S.F. Murray, N. Dean, T.L. Yaksh, M. Butler Inhibition of spinal protein kinase Calpha expression by an antisense oligonucleotide attenuates morphine infusion-induced tolerance Neuroscience 113 2002 99 107
23. J.C. Hunter, V.L. Woodburn, C. Durieux, E.K. Pettersson, J.A. Poat, J. Hughes C-fos antisense oligodeoxynucleotide increases formalin-induced nociception and regulates preprodynorphin expression Neuroscience 65 1995 485 492
24. H. Inoue, Y. Hayase, A. Imura, S. Iwai, K. Miura, E. Ohtsuka Synthesis and hybridization studies on two complementary nona(2′-O-methyl) ribonucleotides Nucleic Acids Res 15 1987 6131 6148
25. S.K. Joshi, X. Su, F. Porreca, G.F. Gebhart Kappa-opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action J Neurosci 20 2000 5874 5879
26. J. Lai, M.S. Gold, C.S. Kim, D. Bian, M.H. Ossipov, J.C. Hunter, F. Porreca Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8 Pain 95 2002 143 152
27. A.I. Lamond, B.S. Sproat Antisense oligonucleotides made of 2′-O-alkylRNA their properties and applications in RNA biochemistry FEBS Lett 325 1993 123 127
28. S.L. Loke, C.A. Stein, X.H. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J.S. Cohen, L.M. Neckers Characterization of oligonucleotide transport into living cells Proc Natl Acad Sci USA 86 1989 3474 3478
29. R.A. McKay, L.J. Miraglia, L.L. Cummins, S.R. Owens, H. Sasmor, N.M. Dean Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-a expression J Biol Chem 274 1999 1715 1722
30. H. Mizoguchi, M. Narita, H. Nagase, L.F. Tseng Antisense oligodeoxynucleotide to a delta-opioid receptor blocks the antinociception induced by cold water swimming Regul Pept 59 1995 255 259
31. B.P. Monia, E.A. Lesnik, C. Gonzalez, W.F. Lima, D. McGee, C.J. Guinosso, A.M. Kawasaki, P.D. Cook, S.M. Freier Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression J Biol Chem 268 1993 14514 14522
32. D. Nakai, T. Seita, T. Terasaki, S. Iwasa, Y. Shoji, Y. Mizushima, Y. Sugiyama Cellular uptake mechanism for oligonucleotides involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15 J Pharmacol Exp Ther 278 1996 1362 1372
33. S. Peng Ho, V. Livanov, W. Zhang, J. Li, T. Lesher Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS Brain Res Mol Brain Res 62 1998 1 11
34. G. Pezeshki, B. Schobitz, T. Pohl, J.M. Reul Intracerebroventricular administration of missense oligodeoxynucleotide induces interleukin-6 mRNA expression in brain and spleen of rats Neurosci Lett 217 1996 97 100
35. F. Plenat, N. Klein-Monhoven, B. Marie, J.M. Vignaud, A. Duprez Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice an autoradiographic, immunohistological, and direct fluorescence microscopy study Am J Pathol 147 1995 124 135
36. M. Rydh-Rinder, O.G. Berge, T. Hokfelt Antinociceptive effects after intrathecal administration of phosphodiester-, 2′-O-allyl-, and C-5-propyne-modified antisense oligodeoxynucleotides targeting the NMDAR1 subunit in mouse Brain Res Mol Brain Res 86 2001 23 33
37. 3H-labeled oligonucleotides: I. Comparison of a phosphodiester and a phosphorothioate Mol Pharmacol 45 1994 932 943
38. B. Schobitz, G. Pezeshki, J.C. Probst, J.M. Reul, T. Skutella, T. Stohr, F. Holsboer, R. Spanagel Centrally administered oligodeoxynucleotides in rats occurrence of non-specific effects Eur J Pharmacol 331 1997 97 107
39. K.M. Standifer, C.C. Chien, C. Wahlestedt, G.P. Brown, G.W. Pasternak Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor Neuron 12 1994 805 810
40. L.S. Stone, L. Vulchanova The pain of antisense in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia Adv Drug Deliv Rev 55 2003 1081 1112
41. M. Tsuda, Y. Shigemoto-Mogami, S. Koizumi, A. Mizokoshi, S. Kohsaka, M.W. Salter, K. Inoue P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury Nature 424 2003 778 783
42. D. Van Oekelen, W.H. Luyten, J.E. Leysen Ten years of antisense inhibition of brain G-protein-coupled receptor function Brain Res Rev 42 2003 123 142
43. T.A. Vickers, S. Koo, C.F. Bennett, S.T. Crooke, N.M. Dean, B.F. Baker Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents a comparative analysis J Biol Chem 278 2003 7108 7118
44. C. Wahlestedt Antisense oligonucleotide strategies in neuropharmacology Trends Pharmacol Sci 15 1994 42 46
45. M. Weiss A novel extravascular input function for the assessment of drug absorption in bioavailability studies Pharmaceut Res 13 1996 1547 1553
46. S. Wu-Pong, T.L. Weiss, C.A. Hunt Antisense c-myc oligonucleotide cellular uptake and activity Antisense Res Dev 4 1994 155 163
47. T.L. Yaksh, T.S. Rudy Chronic catheterization of the spinal subarachnoid space Physiol Behav 17 1976 1031 1036
48. M.R. Young, G. Blackburn-Munro, T. Dickinson, M.J. Johnson, H. Anderson, I. Nakalembe, S.M. Fleetwood-Walker Antisense ablation of type I metabotropic glutamate receptor mGluR1 inhibits spinal nociceptive transmission J Neurosci 18 1998 10180 10188
49. R. Yukhananov, J. Guan, G. Crosby Antisense oligonucleotides to N-methyl-d-aspartate receptor subunits attenuate formalin-induced nociception in the rat Brain Res 930 2002 163 169